Voriconazole for the therapy of mycoses in recipients of solid organ transplants;Voriconazol como terapia de las micosis en receptores de trasplantes de órganos sólidos

Revista Iberoamericana de Micologia

Volumn 24, Issue 3, 2007, Pages 217-222

  Solé, Amparo ^a   Salavert, Miguel ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Antifungal therapy; Invasive fungal infections; Solid organ transplantation; Voriconazole

Indexed keywords

ALANINE AMINOTRANSFERASE; AMPHOTERICIN B LIPID COMPLEX; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; VORICONAZOLE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIFUNGAL ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FUNGAL VIRULENCE; GRAFT RECIPIENT; HEALTH CARE ACCESS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MYCOSIS; ORGAN TRANSPLANTATION; PATIENT COMPLIANCE; PHARMACODYNAMICS; REVIEW; SIDE EFFECT; SURGICAL MORTALITY;

FUNGI;

EID: 35348968451     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-1406(07)70046-3     Document Type: Review

References (33)

1. Almyroudis NG, Sutton DA, Linden P, Rinaldi MG, Fung J, Kusne S. Zygomycosis in solid transplant organs recipients in a tertiary transplant center and review of the literature. Am J Transplant 2006; 6: 2365-2374.
2. Baden LR, Katz JT, Fishman JA, Koziol C, DelVecchio A, Doran M, Rubin RH. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy. Transplantation 2003; 76: 1632-1637.
3. Capitano B, Potoski BA, Husain S, Zhang S, Paterson DL, Studer SM, McCurry KR, Venkataramanan R.Intrapulmonary penetration of voriconazole in lung transplant patients. J Heart Lung Transplant 2005; 24: S109.
4. Christians U, Jacobsen W, Benet LZ, Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002; 41: 813-851.
5. Fortun J, Martin-Davila P, Sanchez MA, Pintado V, Alvarez ME, Sánchez-Sousa A, Moreno S. Voriconazole in the treatment of invasive mold infections in transplant recipients. Eur J Clin Microbiol Infect Dis 2003; 22: 408-413.
6. Gavalda J, Len O, San Juan R, Aguado JM, Fortun J, Lumbreras C, Moreno A, Munoz P, Blanes M, Ramos A, Rufi G, Gurgui M, Torre-Cisneros J, Montejo M, Cuenca-Estrella M, Rodriguez-Tudela JL, Pahissa A; RESITRA (Spanish Network for Research on Infection in Transplantation). Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case control study. Clin Infect Dis 2005; 41: 52-59.
7. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
8. Husain S, Alexander BD, Muñoz P, Avery RK, Houston S, Pruett T, Jacobs R, Dominguez EA, Tollemar JG, Baumgarten K, Yu CM, Wagener MM, Linden P, Kusne S, Singh N. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 2003; 37: 221-229.
9. Husain S, Munoz P, Forrest G, Alexander BD, Somani J, Brennan K, Wagener MM, Singh N. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 2005; 40: 89-99.
10. Husain S, Zaldonis D, Kusne S, Kwak EJ, Paterson DL, McCurry KR. Variation in antifungal prophylaxis strategies in lung transplantation. Transpl Infect Dis 2006; 8: 213-218.
11. Husain S, Paterson DL, Studer S, Pilewski J, Crespo M, Zaldonis D, Shutt K, Pakstis DL, Zeevi A, Johnson B, Kwak EJ, McCurry KR. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006; 6: 3008-3016.
12. Kotloff RM, Ahya VN, Crawford SW. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2004; 170: 22-48.
13. Marik PE. Fungal infections in solid organ transplantation. Expert Opin Pharmacother 2006; 7: 297-305.
14. Musk M, Chambers D, Chin W, Murray R, Gabbay E. Successful treatment of disseminated Scedosporium infection in 2 lung transplant recipients: Review of the literature and recommendations for management. J Heart Lung Transplant 2006; 25: 1269-1272.
15. Pemán J, Salavert M, Cantón E, Jarque I, Román E, Zaragoza R, Viudes A, Gobernado M. Voriconazole in the management of nosocomial invasive fungal infections. Therapeutics and Clinical Risk Management 2006; 2: 1-30.
16. Perlroth MG, Miller J. Pseudoallescheria boydii pneumonia and empyema a rare complication of heart transplantation cured with voriconazole. J Heart Lung Transplant 2004; 23: 647-649.
17. Philips JA, Marty FM, Stone RM, Koplan BA, Katz JT, Baden LR. Torsades de pointes associated with voriconazole use. Transplant Infectious Dis 2007; 9: 33-36.
18. Sahi H, Avery RK, Minai OA, Hall G, Metha AC, Raina P, Budev M. Scedosporium apioespermun (Pseudoallescheria boydii) infection in lung transplant patients. J Heart Lung Transplant 2007; 26: 350-356.
19. San Juan Garrido R, Aguado JM, Lumbreras C, Díaz-Pedroche C, López-Medrano F, Lizasoain M, Gavalda J, Montejo M, Moreno A, Gurguí M, Torre-Cisneros J; RESITRA Network, Spain. Incidence, clinical characteristics and risk factor late infection in solid organ transplant recipients. Data fron RESITRA study group. Am J Transplant 2007; 7: 964-971.
20. Schwartz S, Ruhnke M, Ribaud P, Corey L, Driscoll T, Cornely OA, Schuler U, Lutsar I, Troke P, Thiel E. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005; 106: 2641-2645.
21. Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med 2006; 173: 707-717.
22. Singh N. Fungal infections in the recipients of solid organ transplantation. Infect Dis Clin North Am 2003; 17: 113-134.
23. Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant 2003; 22: 258-266.
24. Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005; 18: 44-69.
25. Singh N, Limaye A, Forrest G, Safdar N, Muñoz P, Pursell K, Houston S, Rosso F, Montoya JG, Patton PR, Del Busto R, Aguado JM, Wagener MM, Husain S. Late-onset invasive aspergillosis in organ transplant recipients in the current era. Med Mycol 2006; 44: 445-449.
26. Singh N, Limaye AP, Forrest G, Safdar N, Muñoz P, Pursell K, Houston S, Rosso F, Montoya JG, Patton P, Del Busto R, Aguado JM, Fisher RA, Klintmalm GB, Miller R, Wagener MM, Lewis RE, Kontoyiannis DP, Husain S. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: A prospective, multicenter, observational study. Transplantation 2006; 81: 320-326.
27. Sole A, Morant P, Salavert M, Pemán J, Morales P and the Valencia Lung Transplant Group. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect 2005; 11: 359-365.
28. Trifilio S, Pennick G, Pi J, Zook J, Golf M, Kaniecki K, Singhal S, Williams S, Winter J, Tallman M, Gordon L, Frankfurt O, Evens A, Mehta J. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007; 109: 1532-1535.
29. Trullas JC, Cervera C, Benito N, de la Bellacasa JP, Agusti C, Rovira M, Mas A, Navasa M, Cofan F, Ricart MJ, Pérez-Villa F, Moreno A. Invasive pulmonary aspergillosis in solid organ and bone marrow transplant recipients. Transplant Proc 2005; 37: 4091-4093.
30. Viscoli C. Combination therapy for invasive aspergillosis. Clin Infect Dis 2004; 39: 803-805.
31. Windham H, Lee JY, Hays SR, Leard LE, Golden JA, de Marco T, Hoopes C, Boettger RF. Sirolimus dose adjustment in heart and lung transplant recipients on voriconazole therapy. J Heart Lung Transplant 2007; 26: S228.
32. Wieland T, Liebold A, Jagiello M, Retzl G, Birnbaum DE. Superiority of voriconazole over amphotericin B in the treatment of invasive aspergillosis after heart transplantation. J Heart Lung Transplant 2005; 24: 102-104.
33. Zoumot Z, Carby M, Hall AV. Radiological resolution of cavitating Aspergillus fumigatus infection following treatment with oral voriconazole in two lung transplant recipients. J Eur Soc Organ Transplant 2006; 19: 688-690.